• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Invasive fungal infections after CLAG-M/CLAG chemotherapy for acute myeloid leukemia and high-grade myeloid neoplasms.

作者信息

Lindsay Julian, Walti Carla S, Halpern Anna B, Xie Hu, Chung E Lisa, Schonhoff Kelda G, Huebner Emily M, Cheng Guang-Shing, Kimball Louise E, Leisenring Wendy M, Greenwood Matthew, Chen Sharon C-A, Kong David C M, Slavin Monica A, Boeckh Michael, Fredricks David N, Liu Catherine, Pergam Steven A, Walter Roland B, Hill Joshua A

机构信息

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.

National Centre for Infection in Cancer, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

出版信息

Blood Adv. 2023 Jul 11;7(13):3140-3145. doi: 10.1182/bloodadvances.2022009562.

DOI:10.1182/bloodadvances.2022009562
PMID:36790925
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10362529/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54b7/10362529/0ec2ed542d1e/BLOODA_ADV-2022-009562-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54b7/10362529/d6404db859b7/BLOODA_ADV-2022-009562-fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54b7/10362529/0ec2ed542d1e/BLOODA_ADV-2022-009562-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54b7/10362529/d6404db859b7/BLOODA_ADV-2022-009562-fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54b7/10362529/0ec2ed542d1e/BLOODA_ADV-2022-009562-gr1.jpg

相似文献

1
Invasive fungal infections after CLAG-M/CLAG chemotherapy for acute myeloid leukemia and high-grade myeloid neoplasms.急性髓系白血病和高级别髓系肿瘤患者接受CLAG-M/CLAG化疗后的侵袭性真菌感染。
Blood Adv. 2023 Jul 11;7(13):3140-3145. doi: 10.1182/bloodadvances.2022009562.
2
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.CLAG-M 强化化疗与 7+3 方案治疗 AML 和其他高级别髓系肿瘤后的感染并发症。
Leukemia. 2023 Feb;37(2):298-307. doi: 10.1038/s41375-022-01786-9. Epub 2022 Dec 12.
3
Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: Analysis of survival after 'CLAG-M' vs. 'MEC'.基于米托蒽醌的挽救性治疗方案在梅奥诊所癌症中心复发性或难治性急性髓系白血病中的疗效：“CLAG-M”与“MEC”方案后的生存分析
Leuk Res. 2020 Mar;90:106300. doi: 10.1016/j.leukres.2020.106300. Epub 2020 Jan 28.
4
Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re-induction chemotherapy. cladribine 联合再诱导化疗可改善复发/难治性急性髓系白血病患儿的预后。
Cancer Med. 2021 Feb;10(3):956-964. doi: 10.1002/cam4.3681. Epub 2021 Jan 24.
5
Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm.在新诊断或复发/难治性急性髓系白血病（AML）或其他高级别髓系肿瘤成人患者中，进行地西他滨序贯（“预激”）与同步给药联合克拉屈滨、阿糖胞苷、粒细胞集落刺激因子（G-CSF）和米托蒽醌（CLAG-M）的随机1期研究。
Leuk Lymphoma. 2020 Jul;61(7):1728-1731. doi: 10.1080/10428194.2020.1728754. Epub 2020 Feb 20.
6
Invasive fungal infection following chemotherapy for acute myeloid leukaemia-Experience from a developing country.急性髓系白血病化疗后继发侵袭性真菌感染-来自发展中国家的经验。
Mycoses. 2017 Oct;60(10):686-691. doi: 10.1111/myc.12646. Epub 2017 Jul 23.
7
Invasive fungal consecutive infections in a patient with acute myeloid leukaemia.一名急性髓系白血病患者的侵袭性真菌连续性感染
Niger J Clin Pract. 2019 Apr;22(4):582-584. doi: 10.4103/njcp.njcp_359_17.
8
Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.克拉屈滨联合大剂量阿糖胞苷、米托蒽醌和粒细胞集落刺激因子（CLAG-M）是一种治疗预后不良的难治性和复发性急性髓系白血病患者的高效挽救方案：波兰成人白血病组的最终报告
Eur J Haematol. 2008 Feb;80(2):115-26. doi: 10.1111/j.1600-0609.2007.00988.x. Epub 2007 Dec 11.
9
Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.挽救性化疗方案治疗急性髓系白血病：一种方案更好吗？CLAG 与 MEC 方案的疗效比较。
Leuk Res. 2011 Mar;35(3):301-4. doi: 10.1016/j.leukres.2010.09.002. Epub 2010 Nov 24.
10
Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.常用挽救性化疗方案对难治性或复发性急性髓系白血病患者的疗效：一项回顾性队列研究。
Medicine (Baltimore). 2018 Sep;97(39):e12102. doi: 10.1097/MD.0000000000012102.

引用本文的文献

1
The USP11/Nrf2 positive feedback loop promotes colorectal cancer progression by inhibiting mitochondrial apoptosis.USP11/Nrf2 正反馈回路通过抑制线粒体凋亡促进结直肠癌进展。
Cell Death Dis. 2024 Dec 1;15(12):873. doi: 10.1038/s41419-024-07188-2.
2
Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial.硼替佐米联合高三尖杉酯碱及阿糖胞苷化疗方案治疗难治性或复发性急性髓系白血病的疗效：一项多中心前瞻性II期临床试验
Front Oncol. 2023 Aug 18;13:1142449. doi: 10.3389/fonc.2023.1142449. eCollection 2023.

本文引用的文献

1
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.CLAG-M 强化化疗与 7+3 方案治疗 AML 和其他高级别髓系肿瘤后的感染并发症。
Leukemia. 2023 Feb;37(2):298-307. doi: 10.1038/s41375-022-01786-9. Epub 2022 Dec 12.
2
Epidemiology of invasive fungal diseases in adults with newly diagnosed acute myeloid leukemia.新诊断急性髓系白血病成人侵袭性真菌病的流行病学
Leuk Lymphoma. 2022 Sep;63(9):2206-2212. doi: 10.1080/10428194.2022.2060504. Epub 2022 Apr 12.
3
Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021.
《2021年血液系统恶性肿瘤和造血干细胞移植抗真菌预防共识指南》
Intern Med J. 2021 Nov;51 Suppl 7:67-88. doi: 10.1111/imj.15588.
4
Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia.高剂量阿糖胞苷、米托蒽醌和聚乙二醇化天冬酰胺酶（HAM-pegA）与高剂量阿糖胞苷、米托蒽醌、克拉屈滨和非格司亭（CLAG-M）作为复发/难治性急性髓系白血病一线挽救性细胞毒性化疗的比较。
J Clin Med. 2020 Feb 16;9(2):536. doi: 10.3390/jcm9020536.
5
Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: Analysis of survival after 'CLAG-M' vs. 'MEC'.基于米托蒽醌的挽救性治疗方案在梅奥诊所癌症中心复发性或难治性急性髓系白血病中的疗效：“CLAG-M”与“MEC”方案后的生存分析
Leuk Res. 2020 Mar;90:106300. doi: 10.1016/j.leukres.2020.106300. Epub 2020 Jan 28.
6
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.针对复发/难治性急性髓系白血病及其他高级别髓系肿瘤，进行克拉屈滨、大剂量阿糖胞苷、米托蒽醌和粒细胞集落刺激因子联合剂量递增米托蒽醌的I/II期试验。
Haematologica. 2019 Apr;104(4):e143-e146. doi: 10.3324/haematol.2018.204792. Epub 2018 Nov 8.
7
Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update.成人癌症相关免疫抑制患者的抗菌预防：ASCO 和 IDSA 临床实践指南更新。
J Clin Oncol. 2018 Oct 20;36(30):3043-3054. doi: 10.1200/JCO.18.00374. Epub 2018 Sep 4.
8
European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia.欧洲成人血液学患者原发性抗真菌预防指南：白血病患者感染欧洲会议更新推荐摘要。
J Antimicrob Chemother. 2018 Dec 1;73(12):3221-3230. doi: 10.1093/jac/dky286.
9
Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.GCLAM 联合剂量递增米托蒽醌治疗初诊 AML 或其他高级别髓系肿瘤的 1/2 期临床试验。
Leukemia. 2018 Nov;32(11):2352-2362. doi: 10.1038/s41375-018-0135-8. Epub 2018 Apr 17.
10
Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients.癌症患者侵袭性真菌感染的流行病学和预防策略更新。
Clin Infect Dis. 2014 Nov 15;59 Suppl 5:S352-5. doi: 10.1093/cid/ciu639.